| Abstract | Doxorubicin hydrochloride is a chemotherapeutic agent highly effective against a wide range of neoplasms. A prime limiting factor to the administration of this drug is cardiotoxicity, which frequently develops when the cumulative dose exceeds 500 mg/sq m. Late cardiomyopathy, which may develop up to a year after therapy has been discontinued, was thought to be rapidly progressive and unresponsive to standard cardiac therapy. An adult who received 475 mg/sq m of doxorubicin hydrochloride experienced a cardiotoxic reaction one year after the completion of therapy. The patient responded to standard cardiac therapy. Resolution of left ventricular dysfunction was verified by echocardiography and radionuclide angiocardiography. |
| Authors | M Cohen, I Kronzon, A Lebowitz |
| Journal | Archives of internal medicine
(Arch Intern Med)
Vol. 142
Issue 8
Pg. 1570-1
(Aug 1982)
ISSN: 0003-9926 UNITED STATES |
| PMID | 7103641
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
|
| Topics |
- Doxorubicin
(adverse effects)
- Female
- Heart Failure
(chemically induced)
- Humans
- Middle Aged
|
